Table 2.

Imaging PET protocol and interpretation in all studies

No.	Author	No of pts	Time between administration and acquisition	Acquisition duration	Glycemia (mg/dL)	Administered FDG dose	PET criteria for the assessment of response to NAT	SUVmax median reduction (%)
1	Kittakaet al [8]	40	120 min	NA	NA	3.7 MBq/kg (mean dose 200 Mbq)	SUVmax reduction	53.0 ± 19.0 in responder 41.0 ± 12.0 in non-responder
2	Ielpo et al. [9]	25	NA	NA	NA	NA	SUV reduction	41.8 (SUVmean 7.9 pre-neoadjuvant 4.6 post-neoadjuvant)
3	Mellon et al. [10]	70	> 90 min	NA	< 200	NA	SUVmax reduction	61.1
4	Akita et al. [11]	83	120 min	NA	104 ± 29.7	3.7 MBq/kg (mean dose 200 Mbq)	SUVmax reduction	44.1 ± 20.3 in poor responder 67.1 ± 15.1 in good responder
5	Sakane et al. [12]	25	60 min	2 min scan/bed position × 11 positions	72–148	3.7 MBq/kg	SULpeak, SUVmax, MTV, TLG	24.0–57.0 in responder 28.0–47.0 in non-responder
6	Dalah et al. [13]	15	45–60 min	NA	NA	10–19 mCi	PERCIST, SULpeak	PERCIST
7	Barnes et al. [14]	104	60 min	NA	< 200	Standard dose of 370 mBq for patients weighing < 55 kg, 444 mBq for patients weighing 55–91 kg, and 518 mBq for patients weighing > 91 kg	SUVmax reduction	44.0–53.0
8	Zimmermann et al. [15]	18	60 min	NA	NA	5 MBq/kg	SUVmax reduction	54.0 (median SUVmax decreased from 8.29 baseline to 3.83 at the end of treatment)
9	Yokose et al. [16]	22	60–75 min	120 s for each bed position in the three-dimensional mode	< 200	4 MBq/kg	PERCIST, SULpeak, SUVmax, MTV, TLG	38.8
10	Barbour et al. [17]	42	NA	NA	NA	NA	NA	No level of reduction in SUVmax from baseline was predictive of early response to therapy
11	Panda et al. [18]	44	60 min	60 min	< 200	10 mCi	SUVmax reduction and SUVgluc reduction	64% change in SUVmax 64% change in SUVgluc

NAT neoadjuvant therapy, MTV metabolic tumor volume, TLG total lesion glycolysis, NA not available, SUV  standardized uptake value, SUL standardized uptake lean